4D Pharma PLC
LBPS
LBPS was delisted on the 24th of June, 2022.
6 hedge funds and large institutions have $2.12M invested in 4D Pharma PLC in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
11% less capital invested
Capital invested by funds: $2.38M → $2.12M (-$260K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$1.16M |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$75.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$115K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$22.9K |
LBPS Hedge Fund Activity: Q3 2021 in Review
6 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in 4D Pharma PLC (LBPS) for Q3 2021, worth a combined $2.12M — down 11% from $2.38M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LBPS positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $1.16M. The largest seller was Morgan Stanley, cutting an estimated $115K.
- 6 institutional investors held 4D Pharma PLC (LBPS) as of Q3 2021, up from 4 in Q2 2021.
- Funds reported $2.12M of 4D Pharma PLC stock for Q3 2021, down 11% quarter-over-quarter.
- 2 funds opened new 4D Pharma PLC positions in Q3 2021 and 0 closed out, a net change of +2 holders.
- The largest 4D Pharma PLC buyer in Q3 2021 was Kepos Capital, an estimated $1.16M added.
- The largest 4D Pharma PLC seller in Q3 2021 was Morgan Stanley, an estimated $115K sold.
Based on aggregated 13F filings for Q3 2021.